US 11,878,041 B2
Compositions and methods for treating the eye
Wen-Hwa Ting Li, Cranbury, NJ (US); Khalid Mahmood, Lawrenceville, NJ (US); Ramine Parsa, Lawrenceville, NJ (US); Manpreet Randhawa, Robbinsville, NJ (US); Mingqi Bai, Jacksonville, FL (US); and Kenneth T. Holeva, Ponte Vedra Beach, FL (US)
Assigned to Johnson & Johnson Surgical Vision, Inc., Irvine, CA (US)
Filed by Johnson & Johnson Surgical Vision, Inc., Irvine, CA (US)
Filed on Nov. 1, 2021, as Appl. No. 17/515,882.
Application 17/515,882 is a division of application No. 16/519,149, filed on Jul. 23, 2019, granted, now 11,166,997.
Claims priority of provisional application 62/703,941, filed on Jul. 27, 2018.
Prior Publication US 2022/0047657 A1, Feb. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 36/064 (2006.01); A61P 27/04 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01)
CPC A61K 36/064 (2013.01) [A61K 9/0048 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61P 27/04 (2018.01)] 8 Claims
1. A method for treating a patient having decreased or low-level production, release, delivery, and/or excretion of hyaluronic acid from and/or in the cornea comprising the step of topically administering to the eye of the patient an ophthalmologic composition comprising:
i) a safe and effective amount of one or more extracts of Pichia anomala to achieve a Pichia anomala extract concentration in the corneal fluid in the corneal tissues of the eye of at least about 0.3 mg/ml, wherein the Pichia anomala extract is characterized as having:
a) a solids content of between 26 and 40 g/l,
b) a pH between 6.0 and 7.0,
c) a protein content between 4 and 90 g/l, and
d) a sugars content ranging between 18 and 29 g/l;
ii) a safe and effective amount of a permeation enhancer; and
iii) an ophthalmologically acceptable carrier.